Seleno-short-chain chitosan induces apoptosis in human breast cancer cells through mitochondrial apoptosis pathway in vitro

Wu, Di; Zhao, Yaofeng; Fu, Shengnan; Zhang, Jianbo; Wang, Wenhang; Yan, Zhexian; Guo, Heng; Liu, Anjun

doi:10.1080/15384101.2018.1464845

Cited by 8 publications

(3 citation statements)

References 57 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important observation we had was that CH-AuNPs did induce changes in the cell cycle of leukemic cells, as we determined previously in HeLa and MCF-710 and as shown in a study done in A549 lung cancer cells treated with CH-AuNPs 35. However, although CH-AuNPs do not induce cell cycle arrest in different cell types, SSCC induced cell cycle arrest in G2 phase in K562 cells34 and in MCF-7 and BT-20 cells 36. These differences could be due to the purity or structure of CH molecule itself, which is different from the AuNPs.…”

Section: Discussionsupporting

confidence: 68%

Chitosan gold nanoparticles induce different ROS-dependent cell death modalities in leukemic cells

Martínez‐Torres¹,

Lorenzo-Anota²,

García-Juárez³

et al. 2019

IJN

View full text Add to dashboard Cite

BackgroundNanotechnology proposes the use of gold nanoparticles (AuNPs) for drug delivery, diagnosis, and treatment of cancer. Leukemia is a type of hematopoietic cancer that results from the malignant transformation of white blood cells. Chitosan-coated AuNPs (CH-AuNPs) are cell death inductors in HeLa and MCF-7 cancer cells without affecting peripheral blood mononuclear cells (PBMC). Considering the selectivity and versatile cytotoxicity of CH-AuNPs, we evaluated whether their selectivity is due to the cell lineage or the characteristics of the cancer cells, by assessing its cytotoxicity in leukemic cells. Moreover, we further examined the cell death mechanism and assessed the implication of nuclear damage, autophagosome formation, and the cell death mechanism induced in leukemic cells.Materials and methodsWe synthesized CH-AuNPs by chemical methods and analyzed their cell death capacity in a T-acute lymphocytic leukemia cell line (CEM), in a chronic myeloid leukemia cell line (K562), and in healthy cells from the same lineage (PBMC and bone marrow, BM, cells). Then, we assessed ROS generation and mitochondrial and nuclear damage. Finally, we evaluated whether cell death occurred by autophagy, apoptosis, or necroptosis, and the role of ROS in this mechanism.ResultsWe found that CH-AuNPs did not affect PBMC and BM cells, whereas they are cytotoxic in a dose-dependent manner in leukemic cells. ROS production leads to mitochondrial and nuclear damage, and cell death. We found that CH-AuNPs induce apoptosis in CEM and necroptosis in K562, both undergoing autophagy as a pro-survival mechanism.ConclusionCH-AuNPs are selective cell death inductors in hematologic cancer cells, without affecting their healthy counterparts. Cell death induced by CH-AuNPs is independent of the cancer cell type; however, its mechanism is different depending on the type of leukemic cells.

show abstract

Section: Discussionsupporting

confidence: 68%

Chitosan gold nanoparticles induce different ROS-dependent cell death modalities in leukemic cells

Martínez‐Torres¹,

Lorenzo-Anota²,

García-Juárez³

et al. 2019

IJN

View full text Add to dashboard Cite

show abstract

“…Too many Fas/FasL pathway associated proteins were expressed abnormally in cancer ( Gao et al, 2020 ). Chitosan may regulate the expression of apoptosis associated proteins, subsequently activated the cleavage of caspase-9 and caspase-3, which finally induced apoptosis in mitochondrial pathway ( Wu et al, 2018 ; Wu et al, 2020 ).…”

Section: Chitosan: Source Structure Physicochemical Properties and Ap...mentioning

confidence: 99%

Recent Advances in Chitosan and its Derivatives in Cancer Treatment

Ding

Guo

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer has become a main public health issue globally. The conventional treatment measures for cancer include surgery, radiotherapy and chemotherapy. Among the various available treatment measures, chemotherapy is still one of the most important treatments for most cancer patients. However, chemotherapy for most cancers still faces many problems associated with a lot of adverse effects, which limit its therapeutic potency, low survival quality and discount cancer prognosis. In order to decrease these side effects and improve treatment effectiveness and patient’s compliance, more targeted treatments are needed. Sustainable and controlled deliveries of drugs with controllable toxicities are expected to address these hurdles. Chitosan is the second most abundant natural polysaccharide, which has excellent biocompatibility and notable antitumor activity. Its biodegradability, biocompatibility, biodistribution, nontoxicity and immunogenicity free have made chitosan become a widely used polymer in the pharmacology, especially in oncotherapy. Here, we make a brief review of the main achievements in chitosan and its derivatives in pharmacology with a special focus on their agents delivery applications, immunomodulation, signal pathway modulation and antitumor activity to highlight their role in cancer treatment. Despite a large number of successful studies, the commercialization of chitosan copolymers is still a big challenge. The further development of polymerization technology may satisfy the unmet medical needs.

show abstract

“…[33][34][35] Previous studies have confirmed that caspases and Bcl-2 family proteins, such as Bax and Bcl-2, serve important roles in the mitochondrial apoptotic pathway. [36][37][38] Mortenson et al 39 demonstrated that bortezomib triggered cell apoptosis in small cell lung cancer via decreasing Bcl-2 levels. The results of the present study revealed that nitroxoline markedly decreased the level of Bcl-2, and increased the levels of Bax, cleaved PARP and cleaved caspase-3 in a concentration-dependent manner in H929 and RPMI8226 cells.…”

Section: Discussionmentioning

confidence: 99%

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis

Zheng

et al. 2020

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Background: Multiple myeloma (MM) is the second most common hematological neoplasm. Wide administration of bortezomib significantly improves the survival of MM patients compared with conventional chemotherapy. Bromodomain-containing protein 4 (BRD4) inhibitors also have been demonstrated to retard cell proliferation and induce cellular apoptosis in various cancers. However, it is unclear whether the BRD4 inhibitor nitroxoline plus bortezomib has a synergistic anti-tumor effect on MM. Methods: Cell viability was determined via 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cycle and cell apoptosis were assessed via flow cytometry. Protein expression levels were determined via western blotting. The expression of apoptosis-related proteins in xenograft tissue were detected by means of immunohistochemistry. Results: Treatment with nitroxoline or bortezomib suppressed cell proliferation, and caused G0/G1 phase arrest and apoptosis in H929 and RPMI8226 cells. Furthermore, nitroxoline intensified the retardation of cell proliferation, as well as further enhanced the G0/G1 phase arrest and apoptosis induced by bortezomib in H929 and RPMI8226 cells. The western blot analysis revealed that nitroxoline or bortezomib treatment markedly diminished the levels of Bcl-2 and cyclin D1, and increased the levels of p21, Bax, cleaved PARP and cleaved caspase-3. Combination of these two agents was observed to result in further marked changes on these levels compared with nitroxoline or bortezomib treatment alone. What is more, in the xenograft tumor model, combinative treatment markedly inhibited tumor growth compared with the single drug treatment. Conclusion: Combination of bortezomib with nitroxoline has a synergistic anti-tumor activity in MM cells and may be a novel treatment method for MM.

show abstract

Seleno-short-chain chitosan induces apoptosis in human breast cancer cells through mitochondrial apoptosis pathway in vitro

Cited by 8 publications

References 57 publications

<p>Chitosan gold nanoparticles induce different ROS-dependent cell death modalities in leukemic cells</p>

<p>Chitosan gold nanoparticles induce different ROS-dependent cell death modalities in leukemic cells</p>

Recent Advances in Chitosan and its Derivatives in Cancer Treatment

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis

Contact Info

Product

Resources

About